A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
Incyte Corporation
Teva Branded Pharmaceutical Products R&D, Inc.
Sanofi
Ocellaris Pharma, Inc.
Synthorx, Inc, a Sanofi company
Shasqi, Inc.
Sanofi
NuCana plc
CytomX Therapeutics
Numab Therapeutics AG
Thomas Jefferson University
Celgene
Aminex Therapeutics, Inc.
23andMe, Inc.
Teon Therapeutics, Inc.
Takeda
Atara Biotherapeutics
University of California, San Diego
Altor BioScience
Altor BioScience
Altor BioScience
Theseus Pharmaceuticals
Sumitomo Pharma America, Inc.
Jounce Therapeutics, Inc.
Shanghai EpimAb Biotherapeutics Co., Ltd.
Medikine, Inc.
Kyowa Kirin Co., Ltd.
National Cancer Institute (NCI)
NKGen Biotech, Inc.
GlaxoSmithKline
SQZ Biotechnologies
Capital Medical University
Teva Branded Pharmaceutical Products R&D, Inc.
University Health Network, Toronto
CytomX Therapeutics
Intellia Therapeutics
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
NBE-Therapeutics AG
Sanofi
Asana BioSciences
4D pharma plc
Bristol-Myers Squibb
Advaxis, Inc.
Bristol-Myers Squibb
GlaxoSmithKline
Swiss Cancer Institute
Molecular Templates, Inc.
Boston Scientific Corporation
Polaris Group